Our non-carrier-added lutetium-177 is a radioactive agent that, when paired with a cancer-seeking molecule, fights the disease by bonding to tumors and metastases and killing cancer cells with minimal damage to surrounding healthy cells.
We're on our way to becoming the world's leading provider of radioisotopes for nuclear medicine. Here's what sets us apart.
High specific activity n.c.a. Lu-177
Produced in accordance with current Good Manufacturing Practice
Drug Master File submitted to U.S. Food and Drug Administration (FDA)
Continuous supply available
U.S.-based production and logistics
Meets or exceeds all European pharmacopeia monograph for lutetium
Each lot individually tested for radiolabeling yield
Currently being used in several active clinical trials underway globally
We’re working on becoming the first vertically integrated manufacturer of lutetium-177 in the world. By eliminating our dependency on a nuclear reactor for Lu-177 production, we will be able to produce more readily available product.
